ReviewInternational journal of clinical and experimental pathology2011
Mammalian target of rapamycin: a central node of complex signaling cascades.
Review in International journal of clinical and experimental pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- Pooled it
- P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis.PloS one · 2017Pooled it
- Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.Haematologica · 2018Trial
- Advancing age is associated with gene expression changes resembling mTOR inhibition: evidence from two human populations.Mechanisms of ageing and development · 2012Trial
- E2F-mediated activation of mTORC1 through the ubiquitin-proteasome system promotes lung adenocarcinoma progression.Cell death & disease · 2026Article
- PSAT1 inhibits mTORC1 activation by preventing Rag heterodimer formation in lung adenocarcinoma.Autophagy · 2026Article
- Gene expression in tumor and adjacent normal tissues in lung adenocarcinoma subtypes.BMC cancer · 2025Article
- Article
- mTORC1, the maestro of cell metabolism and growth.Genes & development · 2025Review
- The first Iranian patient with You-Hoover-Fong syndrome and a review of the literature on 27 cases: expanding the genotypic and phenotypic spectrum.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Review
- mTOR hyperactivity andPathology oncology research : POR · 2024Review
- Article
- FERM domain-containing protein FRMD6 activates the mTOR signaling pathway and promotes lung cancer progression.Frontiers of medicine · 2023Article
- Soluble CD25 imposes a low-zone IL-2 signaling environment that favors competitive outgrowth of antigen-experienced CD25Cellular immunology · 2023Article
- Development of novel DNAJB6-KIAA1522-p-mTOR three-protein prognostic prediction models for CRC.Translational oncology · 2023Article
- Review
- Protocadherin gamma C3: a new player in regulating vascular barrier function.Neural regeneration research · 2023Review
- Role ofOncology letters · 2022Review
- Melatonin protects against ovarian damage by inhibiting autophagy in granulosa cells in rats.Clinics (Sao Paulo, Brazil) · 2022Article
- Roles of mTOR in thoracic aortopathy understood by complex intracellular signaling interactions.PLoS computational biology · 2021Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates cell growth and metabolism in response to diverse external stimuli. In the presence of mitogenic stimuli, mTOR transduces signals that activate the translational machinery and promote cell growth. mTOR functions as a central node in a complex net of signaling pathways that are involved both in normal physiological, as well as pathogenic events. mTOR signaling occurs in concert with upstream Akt and tuberous sclerosis complex (TSC) and several downstream effectors. During the past few decades, the mTOR-mediated pathway has been shown to promote tumorigenesis through the coordinated phosphorylation of proteins that directly regulate cell-cycle progression and metabolism, as well as transcription factors that regulate the expression of genes involved in the oncogenic processes. The importance of mTOR signaling in oncology is now widely accepted, and agents that selectively target mTOR have been developed as anti-cancer drugs. In this review, we highlight the past research on mTOR, including clinical and pathological analyses, and describe its molecular mechanisms of signaling, and its roles in the physiology and pathology of human diseases, particularly, lung carcinomas. We also discuss strategies that might lead to more effective clinical treatments of several diseases by targeting mTOR.
Indexed as
Identifiers
21738819PMC3127069W93053989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.